Telix Pharmaceuticals Limited
TLPPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $5,395 | $8,015 | $6,252 | $3,269 |
| - Cash | $207 | $710 | $119 | $123 |
| + Debt | $418 | $581 | $22 | $17 |
| Enterprise Value | $5,606 | $7,886 | $6,155 | $3,163 |
| Revenue | $593 | $594 | $189 | $282 |
| % Growth | -0.2% | 214.5% | -32.9% | – |
| Gross Profit | $288 | $386 | $124 | $224 |
| % Margin | 48.6% | 64.9% | 65.6% | 79.5% |
| EBITDA | $9 | $77 | $40 | $23 |
| % Margin | 1.5% | 12.9% | 21.3% | 8.2% |
| Net Income | -$3 | $38 | $12 | $20 |
| % Margin | -0.6% | 6.4% | 6.2% | 6.9% |
| EPS Diluted | -0.01 | 0.11 | 0.033 | 0.06 |
| % Growth | -109.4% | 230.3% | -44.8% | – |
| Operating Cash Flow | $27 | $9 | $34 | $11 |
| Capital Expenditures | -$10 | -$20 | -$14 | -$8 |
| Free Cash Flow | $17 | -$11 | $20 | $3 |